Head to Head Analysis: Helius Medical Technologies (NASDAQ:HSDT) and Xcorporeal (OTCMKTS:XCRP)

Helius Medical Technologies (NASDAQ:HSDT) and Xcorporeal (OTCMKTS:XCRP) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

18.6% of Helius Medical Technologies shares are owned by institutional investors. 5.1% of Helius Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Helius Medical Technologies and Xcorporeal”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helius Medical Technologies	$502,000.00	4.06	-$8.85 million	($6.18)	-0.09
Xcorporeal	N/A	N/A	N/A	N/A	N/A

Xcorporeal has lower revenue, but higher earnings than Helius Medical Technologies.

Profitability

This table compares Helius Medical Technologies and Xcorporeal’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Helius Medical Technologies	-1,764.74%	-244.82%	-127.10%
Xcorporeal	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Helius Medical Technologies and Xcorporeal, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Helius Medical Technologies	0	1	1	0	2.50
Xcorporeal	0	0	0	0	0.00

Helius Medical Technologies presently has a consensus price target of $24.00, suggesting a potential upside of 4,287.57%. Given Helius Medical Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than Xcorporeal.

Summary

Helius Medical Technologies beats Xcorporeal on 6 of the 9 factors compared between the two stocks.

About Helius Medical Technologies

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About Xcorporeal

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.